PATENT CLAIM ANALYSIS

Application Number: 15982038
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "249000"]

Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.

Claim (Index 13):
A method of treating a thromboembolic disorder according to  claim 12 , wherein the thromboembolic disorder is selected from the group consisting of arterial cardiovascular thromboembolic disorders, venous cardiovascular thromboembolic disorders, and thromboembolic disorders in the chambers of the heart.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 93.0
- Lexical Diversity: 1.17949
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15643891', '15183051', '14799681', '14350411', '14350417']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.830321608597892
- 35 USC 102 Novelty (BERT): 0.529095576637745
- Combined Prediction Score: 0.8001990054018773
- Mean Citation Score: 315.033496
- Max Citation Score: 316.3271200000001
- Similarity Product: 150.17605895697838

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test